RNS Announcements

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces its unaudited results for the six months to 30 June 2026.

 

Download To view a full version of the results in  PDF format  click here

 

Key Financial Highlights

• Gross revenue +53% to £2.06m (H1 2025: £1.34m)
• Gross profit +66% to £1.245m (H1 2025: £748,000)
• EBITDA profit £151,000* (H1 2025: £112,000 loss)
• Strong cash balance of £1.244m (H1 2025: £1.3m)

*Excluding share-based payments

Operational Highlights

• Five new partnerships established
• Significant growth of existing customer base
• Strong growth in China through Kemin partnership
• Repositioned US strategy for stronger market penetration in 2027
• Recruitment for clinical study to investigate potential impact of LP_LDL® in prediabetes and diabetes

Steen Andersen, CEO of ProBiotix commented: "We are pleased with the performance of the business in the first half of the financial year, and the progress we are making. The active customer base has grown by more than 15% during this period, which reflects the growing demand for effective science-backed preventive cardiometabolic supplement products.

We expect further growth in H2 from APAC and the EMEA regions and going into 2027 through the repositioning of a deeper US offering, expanding sales to include third party distribution and a broadened product positioning to offer LP_LDL® beyond cholesterol health."

 

For further information, please contact:

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

Notes to Editors:

ProBiotix Health is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

The Company has a unique approach; discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.